HIV treatment and prevention on every 2026 New Jersey Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in New Jersey cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
12 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Humana Basic Rx Plan$4.40/moS5884-131 | Wellcare Value Script$22.80/moS4802-139 | Wellcare Classic$28.20/moS4802-078 | Humana Value Rx Plan$35.60/moS5884-183 | HealthSpring Extra Rx$59.90/moS5617-354 | Horizon Medicare Blue Rx Standard$72.30/moS5993-001 | AARP Medicare Rx Saver from UHC$77.40/moS5921-349 | SilverScript Choice$97.40/moS5601-008 | HealthSpring Assurance Rx$109.30/moS5617-018 | Humana Premier Rx Plan$111.90/moS5884-150 | AARP Medicare Rx Preferred from UHC$118.90/moS5921-386 | Horizon Medicare Blue Rx Enhanced$139.10/moS5993-003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 432%QL 180/30d | Tier 440% | Tier 429% | Tier 432%QL 180/30d | Tier 430%QL 300/30d | Tier 445%QL 180/30d | Tier 436%QL 180/30d | Tier 433% | Tier 427%QL 300/30d | Tier 450%QL 180/30d | Tier 433%QL 180/30d | Tier 445%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 530%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 432%QL 30/30d | Tier 440%QL 30/30d | Tier 429%QL 30/30d | Tier 432%QL 30/30d | Tier 430%QL 30/30d | Tier 445%QL 30/30d | Tier 436%QL 30/30d | Tier 433%QL 30/30d | Tier 427%QL 30/30d | Tier 450%QL 30/30d | Tier 433%QL 30/30d | Tier 445%QL 30/30d |
| Tivicaydolutegravir | Tier 525%QL 60/30d | Tier 525% | Tier 525% | Tier 526%QL 60/30d | Tier 430%QL 180/30d | Tier 525%QL 60/30d | Tier 525%QL 60/30d | Tier 525% | Tier 427%QL 180/30d | Tier 533%QL 60/30d | Tier 531%QL 60/30d | Tier 530%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.